Literature DB >> 19472416

DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.

Chandanamali Punchihewa1, Megan Carver, Danzhou Yang.   

Abstract

In probing the mechanism of inhibition of hypoxia inducible factor (HIF-1) by campothecins, we investigated the ability of human topoisomerase I to bind and cleave HIF-1 response element (HRE), which contains the known camptothecin-mediated topoisomerase I cleavage site 5'-TG. We observed that the selection of 5'-TG by human topoisomerase I and topotecan depends to a large extent on the specific flanking sequences, and that the presence of a G at the -2 position (where cleavage occurs between -1 and +1) prevents the HRE site from being a preferred site for such cleavage. Furthermore, the presence of -2 T/A can induce the cleavage at a less preferred TC or TA site. However, in the absence of a more preferred site, the HRE site is shown to be cleaved by human topoisomerase I in the presence of topotecan. Thus, it is implied that the -2 base has a significant influence on the selection of the camptothecin-mediated Topo I cleavage site, which can overcome the preference for +1G. While the cleavage site recognition has been known to be based on the concerted effect of several bases spanning the cleavage site, such a determining effect of an individual base has not been previously recognized. A possible base-specific interaction between DNA and topoisomerase I may be responsible for this sequence selectivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19472416      PMCID: PMC2774443          DOI: 10.1002/pro.138

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  22 in total

1.  DNA relaxation and cleavage assays to study topoisomerase I inhibitors.

Authors:  C Bailly
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.

Authors:  M Valenti; W Nieves-Neira; G Kohlhagen; K W Kohn; M E Wall; M C Wani; Y Pommier
Journal:  Mol Pharmacol       Date:  1997-07       Impact factor: 4.436

4.  Purification of baculovirus-expressed human DNA topoisomerase I.

Authors:  L Stewart; J J Champoux
Journal:  Methods Mol Biol       Date:  1999

5.  A model for the mechanism of human topoisomerase I.

Authors:  L Stewart; M R Redinbo; X Qiu; W G Hol; J J Champoux
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

6.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.

Authors:  M R Redinbo; L Stewart; P Kuhn; J J Champoux; W G Hol
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

7.  Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA.

Authors:  M R Redinbo; J J Champoux; W G Hol
Journal:  Biochemistry       Date:  2000-06-13       Impact factor: 3.162

8.  The role of lysine 532 in the catalytic mechanism of human topoisomerase I.

Authors:  Heidrun Interthal; Paulene M Quigley; Wim G J Hol; James J Champoux
Journal:  J Biol Chem       Date:  2003-10-31       Impact factor: 5.157

9.  Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.

Authors:  A Tanizawa; K W Kohn; G Kohlhagen; F Leteurtre; Y Pommier
Journal:  Biochemistry       Date:  1995-05-30       Impact factor: 3.162

10.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

Authors:  Annamaria Rapisarda; Badarch Uranchimeg; Dominic A Scudiero; Mike Selby; Edward A Sausville; Robert H Shoemaker; Giovanni Melillo
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.